Germany: Time for more medical device SPCs?

Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Germany: Time for more medical device SPCs?

The ultimate purpose of a Supplementary Protection Certificate (SPC) is to compensate a patentee for the time lost due to lengthy regulatory approval processes.

The EU legislation governing SPCs does not explicitly cover medical devices, but only pharmaceuticals and crop protection products. One reason for this may be that medical devices only undergo a rather lean approval process that is merely supervised by a notified body instead of a regulatory authority. Consequently, there have been only exceptional cases where patentees obtained an SPC for a medical device in some EU member states. Most requests are denied.

In May 2017, the new Medical Device Regulation (MDR) and In vitro Diagnostic Medical Device Regulation (IVDMDR) entered into force. There seems to be a general consensus that the Regulations will raise the bar for market approval of medical devices. For example, the Regulations establish a new pre-market scrutiny mechanism, including a pool of experts, that ensures stricter ex-ante control for high-risk devices. One unintended consequence could be that the new Regulations will slow down market approval for medical devices, prompting even more manufacturers to reach for an SPC as compensation.

The ever-growing field of precision medicine, i.e. administration of the most suitable drug for each individual patient, promises improved medical treatments in the future. A crucial aspect of precision medicine is the use of companion diagnostics, defined according to the IVDMDR as a medical device essential for the safe and effective use of a corresponding medicinal product. Before granting market approval for companion diagnostics, the notified body shall "consult" a competent regulatory authority, which could potentially complicate and slow down the approval process.

Further, for highly innovative first-in-class drugs, the companion diagnostic will ideally be co-developed together with the drug, since its early use for patient stratification in clinical trials facilitates monitoring the effects of the new drug. However, the commercial value of the co-developed companion diagnostic is entirely dependent on regulatory approval of the first-in-class drug. It would thus be fair to not only award an SPC for the first-in-class drug but also for its companion diagnostic.

In summary, the regulatory hurdles for the market approval of many medical devices are being set higher, and we may see more cases where an SPC for medical devices may seem reasonable and just (despite medical devices not being explicitly covered by the current SPC regulations). Especially for the emerging field of precision medicine, it remains to be seen if and how the time loss due to regulatory processes can be compensated for and whether SPCs for companion diagnostics could play a part in that compensation.

Jan van Dieck


Maiwald Patentanwalts GmbHElisenhof, Elisenstr 3D-80335, Munich, GermanyTel: +49 89 74 72 660 Fax: +49 89 77 64 24info@maiwald.euwww.maiwald.eu

more from across site and SHARED ros bottom lb

More from across our site

Karl Barnfather’s new patent practice will focus on protecting and enforcing tech innovations in the electronics, AI, and software industries
Partner Ranjini Acharya explains how her Federal Circuit debut resulted in her convincing the court to rule that machine learning technology was not patent-eligible
Paul Hastings and Smart & Biggar also won multiple awards, while Baker McKenzie picked up a significant prize
Burford Capital study finds that in-house lawyers have become more likely to monetise patents, but that their IP portfolios are still underutilised
Robert Reading and Faidon Zisis at Clarivate unpick some of the data surrounding music-related trademarks
China's latest IP litigation statistics and a high-profile hire by O'Melveny were also among the top talking points this week
David Aylen, who spent more than 20 years at Gowling WLG, has joined United Trademark and Patent Services as of counsel in the UAE
Europe is among the most lucrative legal markets for PE firms to bet on, but clients’ reactions will decide whether external investment drives success
Rulings of note covered pre-June 2023 infringements and jurisdiction over non-UPC states, while winners of Managing IP’s EMEA Awards acted in multiple cases
Jason Blair, a former special marks examiner, said Dykema’s Texas presence will help him build deeper connections with clients
Gift this article